Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia Looks Into Funding Diagnostics For Targeted Drugs

This article was originally published in PharmAsia News

Executive Summary

Australian authorities believe they may be able to save billions of dollars by backing development of diagnostic tests for targeted drugs. The government plans to explore the possibility of such a move, which could have an added advantage of preventing harmful side effects. The Australian Centre for Health Research estimated possible savings at more than U.S. $8.5 billion over the next five years. The study, conducted for the center by Deloitte Economics, named strokes, cholesterol, colorectal cancer and depression as among several diseases and drugs that would benefit from targeting. (Click here for more

You may also be interested in...



GSK's Growth Drivers And Cost Containment Offset Pandemic Impact

GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.

L’Oreal’s Mid-COVID Bet Pays Off With Q3 Return To Growth

With many competitor programs on hold during the COVID crisis, L’Oreal dialed up its media investments and launched products over the summer that were postponed from the first quarter, resulting in a return to growth in the firm’s third quarter led by Professional Products and Active Cosmetics.

QUOTED. 29 October 2020. Erik Raadsheer.

Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU. Erik Raadsheer, senior director of Align Technology, expressed concerns.

UsernamePublicRestriction

Register

LL1127674

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel